Asthma

Follow up care with pulmonologist crucial to health outcomes.

Turnover from novel therapeutic target to model systems in clinical use remains a challenge.

Medication will be used as an add-on maintenance therapy in patients aged 12 years and older.

Oxygen therapy use spikes since 2000.

Up to 13% of patients diagnosed with COPD under the GOLD criteria are actually misdiagnosed.

Generic Pulmicort Respules is approved for the treatment of asthma and to serve as prophylactic therapy in children aged 12 months to 8 years.

Sandoz has launched a generic version of AstraZeneca's asthma drug Pulmicort Respules in the US market.

The approximate 1 in 10 asthma patients who have severe disease do not respond to mainstay corticosteroid treatment, even in high doses.

Premature aging of the lung cells plays a factor in pathogenesis.

Asthma's increasingly deleterious morbidity and socioeconomic burden are of tremendous concern to clinicians and public health officials.

Lung function and health status decreases across all levels of severity.

Patients with a burn injury were twice as likely to have been prescribed oxygen in the previous 90 days.

Study finds many patients use propellant-based metered-dose inhalers incorrectly.

Reslizumab targets a key cytokine involved in elevating levels of blood eosinophils.

The FDA is currently reviewing Teva's reslizumab treatment for adult and adolescent asthmatics with symptoms inadequately controlled by inhaled corticosteroid (ICS) regimens.

An FDA advisory committee has unanimously recommended approval for GlaxoSmithKline's mepolizumab severe asthma treatment in adults, but not adolescents.

While some patients may take soy supplements to manage their asthma, a new study suggests there is no solid evidence of improved lung function or clinical outcomes from the supplementation.

Once-daily drug can be used to treat chronic bronchitis and emphysema.

Pharmacists need to remain cognizant of COPD and asthma patient preferences to maintain adherence.

Clinical guidelines and government agencies are increasingly encouraging clinicians to consider patients' treatment preferences when chronic disease is present.

Link found between new onset obstructive sleep apnea and habitual sleepiness.

AstraZeneca and Abbott are teaming up to develop companion diagnostic blood tests that will identify patients with severe asthma who would benefit most from biological tralokinumab therapy.

Asthma controller medications are underused in neighborhoods with high rates of asthma-related emergency room use and hospitalization, but pharmacists are in a prime position to correct it.

The FDA today expanded the indication of fluticasone furoate/vilanterol (Breo Ellipta) for the treatment of asthma.

Difficulty with several aspects of nebulizer use creates treatment hurdles for patients.